Phase 1 N=80 A Study to Test How Well Men Tolerate Different Doses of BI 3006337
Healthy
Primary: Number of Subjects With Drug-related Adverse Events (AEs) After a Single Dose of BI 3006337 — 0; 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs…
Phase 1 N=56 First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts
Rheumatoid Arthritis
Primary: Safety and Tolerability: Adverse Events — 7; 9; 8; 8 number of events
Phase 1 N=16 A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Cough
Primary: Part 1: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Camlipixant — 5811; 4735 Hours*nanograms per milliliter
Phase 1 N=14 A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants
Healthy Volunteers
Primary: Area Under the Plasma Concentration-time Curve From Time Zero (Predose [Day 1]) to Infinity (AUC) for Zilucoplan — 950930; 932740 hour*nanogram per milliliters (h*ng/mL)
Phase 1 N=25 WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Advanced or Metastatic Solid Tumors · Non-Hodgkin Lymphoma
Primary: Incidence of Dose Limiting Toxicities (DLTs) — 0; 0; 1 Participants
Phase 1 N=34 Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days.
Healthy Volunteer
Primary: Area Under the Curve 0-24h — 281.60; 411.35 h*ng/mL
Phase 1 N=13 Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Refractory Multiple Myeloma · Multiple Myeloma in Relapse · Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicities — 1; 0; 0 Participants
Phase 1 N=498 A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab — 12.9; 13.5 microgram per milliliter (ug/mL)
Phase 1 N=15 A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Melanoma
Primary: Number of Participants Experiencing Clinical and/or Laboratory Dose-limiting Toxicities — 0 Participants
Phase 1 N=247 A Study of LY3039478 in Participants With Advanced Cancer
Neoplasms · Neoplasm Metastasis · Lymphoma
Primary: Part A and F: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 1 N=86 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Platinum-resistant Ovarian Cancer · Fallopian Tube Cancer · Epithelial Ovarian Cancer
Primary: Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab — 20; 65 Participants
Phase 1 N=207 Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers
Healthy Male Subjects
Primary: Maximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia® — 7662.99; 7742.64; 8033.14 ng/ml
Phase 1 N=28 Relative Bioavailability of Evobrutinib Tablet Batches
Healthy
Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib — 198; 164; 207; 205 hour×nanogram per milliliter…
Phase 1 N=42 A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
Healthy Study Participants
Primary: Maximum Plasma Concentration (Cmax) of UCB0599 in Part A — 876.2; 724.6; 618.0; 449.3 nanograms per milliliter (ng/mL)